India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The Florida Treasure Coast started the new year with a surge of 1,905 new home listings—up 22 percent from last January—signaling one of the strongest inventory jumps in years. While Martin County saw its median home price drop by nearly $100,000, nearby St. Lucie and Indian River counties continued to rise, creating a uniquely mixed market. With sales climbing and inventory levels shifting toward a more buyer-friendly landscape, 2026 is shaping up to be an active and opportunity-rich year for both seasoned agents and those entering the real estate field.
A unanimously passed House bill, HB 767, aims to require insurers to publicly disclose rate and premium data—giving Floridians long‑awaited clarity on rising costs. If approved by the Senate, the measure could significantly impact homeowners, real estate agents, mortgage professionals, and insurance specialists by increasing consumer trust and revealing how insurers calculate premiums.
U.S. mortgage rates have dipped to 5.98 percent, breaking below the 6 percent mark for the first time since 2022 and giving the spring home-buying season a fresh boost. With rates falling for the third straight week and buyer interest rising, experts say this shift could encourage more market activity—though many homeowners with ultra‑low pandemic-era rates may still hesitate to sell.
Artificial intelligence is rapidly transforming real estate, from listing creation to MLS infrastructure, forcing the industry to rethink how data is used, altered and protected. With AI tools making it easier than ever to modify photos, automate marketing and process sensitive documents, MLSs and state regulators are racing to establish new guardrails that ensure accuracy, privacy and consumer protection without slowing innovation.
Today’s real estate pros juggle nonstop client demands, constant marketing, and mountains of paperwork—but AI is stepping in as the ultimate assistant. From instant lead responses and personalized follow-up messages to predictive pricing tools and automated transaction support, agents are using AI to save hours, boost production, and stay competitive. The future of real estate belongs to professionals who combine their human touch with smart technology, and the shift is already happening.
A landmark US Supreme Court decision striking down the use of emergency powers to impose broad tariffs has upended global trade expectations, lifted equity markets, and sent businesses scrambling to understand what comes next. While GDP slowed and inflation rose, markets reacted positively as the ruling removed a major source of uncertainty for importers, exporters, and investors. With the old tariff framework dismantled and new targeted measures on the horizon, industries from real estate to finance are bracing for shifting economic conditions that could influence everything from consumer spending to investment strategy.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
